Proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs) are quite possibly the most maturely developed TPD methods. With this evaluation, we target equally preclinical experiments and medical trials to supply an extensive summary of the protection and clinical usefulness of PROTACs and MGDs in hematologic malignancies over the